Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG).

PloS one·2026
Same author

Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.

Lung cancer (Amsterdam, Netherlands)·2024
Same author

Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2023
Same author

Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort.

Frontiers in oncology·2023

Related Experiment Video

Updated: May 18, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Developments in early-stage NSCLC: advances in radiotherapy.

N E Verstegen1, F J Lagerwaard, S Senan

  • 1Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|September 19, 2012
PubMed
Summary

Stereotactic ablative radiotherapy (SABR) offers excellent results and mild toxicity for elderly patients with early-stage non-small-cell lung cancer. Ongoing trials compare SABR with surgery for borderline operable patients.

Area of Science:

  • Oncology
  • Radiotherapy
  • Pulmonology

Background:

  • Increasing prevalence of elderly patients diagnosed with early-stage non-small-cell lung cancer (NSCLC).

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Related Experiment Videos

Last Updated: May 18, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

  • Elderly patients often present with comorbidities, increasing surgical risks.
  • Stereotactic ablative radiotherapy (SABR) has emerged as a viable treatment option for these patients.